Literature DB >> 1906286

A specific and potent immunotoxin composed of antibody ZME-018 and the plant toxin gelonin.

M G Rosenblum1, J L Murray, L Cheung, R Rifkin, S Salmon, R Bartholomew.   

Abstract

Murine monoclonal antibody ZME-018 recognizes a 240 Kda glycoprotein present on the surface of most human melanoma cells and on over 80% of human biopsy specimens tested. Gelonin is a ribosome-inactivating plant toxin similar in nature and rivaling the activity of ricin A chain. ZME-018 was coupled to purified gelonin using the reagents SPDP and 2-iminothiolane. The ZME-gelonin conjugate was purified by S-300 Sephacryl and Blue Sepharose chromatography, removing unreacted gelonin and antibody, respectively. PAGE analysis showed that ZME was coupled to 1, 2, or 3 gelonin molecules. The ZME-gelonin conjugate was 10(6)-fold more active than gelonin itself in inhibiting the growth of log-phase human melanoma cells in culture. The immunoconjugate was not cytotoxic to antigen negative T-24 (human bladder carcinoma) cells. Treatment of melanoma cells with recombinant IFN-alpha or TNF substantially augmented the cytotoxicity of the immunoconjugate while treatment with IFN-gamma had a minor effect. Using the human tumor colony assay of melanoma cells obtained from fresh biopsy specimens, greater than 90% growth suppression was observed in 2 of 4 samples tested at a concentration of 250 ng/ml. In addition, 25% growth suppression was observed with a third sample tested, and no growth suppression was observed in 1 sample. Thus, clonogenic melanoma cells are sensitive in vitro to the cytotoxic activity of this immunotoxin at concentrations which we presume are pharmacologically relevant.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1906286

Source DB:  PubMed          Journal:  Mol Biother        ISSN: 0952-8172


  16 in total

Review 1.  Immunotoxins for targeted cancer therapy.

Authors:  Robert J Kreitman
Journal:  AAPS J       Date:  2006-08-18       Impact factor: 4.009

2.  The vascular-ablative agent VEGF(121)/rGel inhibits pulmonary metastases of MDA-MB-231 breast tumors.

Authors:  Sophia Ran; Khalid A Mohamedali; Troy A Luster; Philip E Thorpe; Michael G Rosenblum
Journal:  Neoplasia       Date:  2005-05       Impact factor: 5.715

3.  The antimelanoma immunocytokine scFvMEL/TNF shows reduced toxicity and potent antitumor activity against human tumor xenografts.

Authors:  Yuying Liu; Weihe Zhang; Lawrence H Cheung; Ting Niu; Qingping Wu; Chun Li; Carolyn S Van Pelt; Michael G Rosenblum
Journal:  Neoplasia       Date:  2006-05       Impact factor: 5.715

4.  A potent and specific immunotoxin for tumor cells expressing disialoganglioside GD2.

Authors:  K Mujoo; R A Reisfeld; L Cheung; M G Rosenblum
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

5.  Biodistribution, pharmacokinetics, and nuclear imaging studies of 111In-labeled rGel/BLyS fusion toxin in SCID mice bearing B cell lymphoma.

Authors:  Xiaoxia Wen; Mi-Ae Lyu; Rui Zhang; Wei Lu; Qian Huang; Dong Liang; Michael G Rosenblum; Chun Li
Journal:  Mol Imaging Biol       Date:  2011-08       Impact factor: 3.488

6.  The vascular-targeting fusion toxin VEGF121/rGel inhibits the growth of orthotopic human bladder carcinoma tumors.

Authors:  Khalid A Mohamedali; Daniel Kedar; Paul Sweeney; Ashish Kamat; Darren W Davis; Beryl Y Eve; Samuel Huang; Philip E Thorpe; Colin P Dinney; Michael G Rosenblum
Journal:  Neoplasia       Date:  2005-10       Impact factor: 5.715

7.  Cell Internalization Studies of Gadofullerene-(ZME-018) Immunoconjugates into A375m Melanoma Cells.

Authors:  Christopher Scott Berger; John W Marks; Robert D Bolskar; Michael G Rosenblum; Lon J Wilson
Journal:  Transl Oncol       Date:  2011-12-01       Impact factor: 4.243

8.  Characterization of the increased cytotoxicity of gelonin anti-T cell immunoconjugates compared with ricin A chain immunoconjugates.

Authors:  D M Fishwild; H M Wu; S F Carroll; S L Bernhard
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

9.  An antimelanoma immunotoxin containing recombinant human tumor necrosis factor: tissue disposition, pharmacokinetic, and therapeutic studies in xenograft models.

Authors:  M G Rosenblum; L Cheung; K Mujoo; J L Murray
Journal:  Cancer Immunol Immunother       Date:  1995-05       Impact factor: 6.968

10.  Pharmacokinetics, tissue distribution, and in vivo antitumor effects of the antimelanoma immunotoxin ZME-gelonin.

Authors:  K Mujoo; L Cheung; J L Murray; M G Rosenblum
Journal:  Cancer Immunol Immunother       Date:  1995-05       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.